Bharat Biotech asked to conduct Phase III trials for its intranasal vaccine

The company had also sought approval from the SEC to use its intranasal vaccine as a booster dose, to which the SEC asked the company to submit a revised protocol. The company plans to administer its nasal vaccine as a booster dose for those who have received two shots of a Covid-19 vaccine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3HBb8fR
via IFTTT